| Literature DB >> 30811976 |
Florinda Meléndez-Rodríguez1, Andrés A Urrutia2, Doriane Lorendeau3, Gianmarco Rinaldi3, Olga Roche4, Nuray Böğürcü-Seidel5, Marta Ortega Muelas6, Claudia Mesa-Ciller2, Guillermo Turiel2, Antonio Bouthelier2, Pablo Hernansanz-Agustín2, Ainara Elorza2, Elia Escasany2, Qilong Oscar Yang Li2, Mar Torres-Capelli2, Daniel Tello2, Esther Fuertes2, Enrique Fraga2, Antonio Martínez-Ruiz1, Belen Pérez7, Jose Miguel Giménez-Bachs8, Antonio S Salinas-Sánchez8, Till Acker5, Ricardo Sánchez Prieto9, Sarah-Maria Fendt3, Katrien De Bock10, Julián Aragonés11.
Abstract
Cellular aspartate drives cancer cell proliferation, but signaling pathways that rewire aspartate biosynthesis to control cell growth remain largely unknown. Hypoxia-inducible factor-1α (HIF1α) can suppress tumor cell proliferation. Here, we discovered that HIF1α acts as a direct repressor of aspartate biosynthesis involving the suppression of several key aspartate-producing proteins, including cytosolic glutamic-oxaloacetic transaminase-1 (GOT1) and mitochondrial GOT2. Accordingly, HIF1α suppresses aspartate production from both glutamine oxidation as well as the glutamine reductive pathway. Strikingly, the addition of aspartate to the culture medium is sufficient to relieve HIF1α-dependent repression of tumor cell proliferation. Furthermore, these key aspartate-producing players are specifically repressed in VHL-deficient human renal carcinomas, a paradigmatic tumor type in which HIF1α acts as a tumor suppressor, highlighting the in vivo relevance of these findings. In conclusion, we show that HIF1α inhibits cytosolic and mitochondrial aspartate biosynthesis and that this mechanism is the molecular basis for HIF1α tumor suppressor activity.Entities:
Keywords: GOT1; GOT2; HIF1α; aspartate biosynthesis; cancer; glutamine; oxygen; proliferation; renal cell carcinoma
Mesh:
Substances:
Year: 2019 PMID: 30811976 DOI: 10.1016/j.celrep.2019.01.106
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423